Finch Therapeutics Provides Business Update
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
Finch Therapeutics to Participate in Upcoming June Investor Conferences
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
